The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 24, 1999
Filed:
Sep. 06, 1996
Gary R Gustafson, Bedford, MA (US);
David G Powers, Maynard, MA (US);
Mark A Wuonola, Waltham, MA (US);
Scriptgen Pharmaceuticals, Inc., Waltham, MA (US);
Abstract
This invention provides a compound having the formula: ##STR1## wherein R.sup.1 and R.sup.3 independently are hydrogen, --CHO, --COCH.sub.3, --COR.sup.7, --A--Ar--(Q).sub.z, etc.; wherein D is a C.sub.1-6 linear, C.sub.3-8 branched or cyclic group having from 4 to about 15 atoms, consisting of C, etc.; wherein D is unsubstituted or substituted with one or more groups independently selected from the group consisting of --OH, NH.sub.2, --NHR.sub.7, etc.; wherein each Q is independently --CNH(NHY), --NHCNH(NHY), --SO.sub.2 W, --SOW, etc.; wherein Y is hydrogen, alkyl, alkenyl, --B--NH.sub.2, --B--NHR.sup.8, etc.; wherein W is alkyl, alkenyl, --B--NH.sub.2, etc.; wherein A nd B independently are a bond, or a C.sub.1-6 linear, C.sub.3-8 branched or cyclic linking group having from 1 to about 15 atoms, consisting of C, optionally interrupted by N, S, P and O; wherein A and B independently are unsubstituted or substituted with --OH, NH.sub.2, etc.; wherein R.sup.7 is an alkyl, a branched alkyl, etc.; wherein R.sup.8, R.sup.9, and R.sup.10 are independently represented by hydrogen, alkyl, branched alkyl, etc.; wherein x is 0, 1 or 2; and z is 0, 1, 2, or 4; wherein R.sup.1 ' and R.sup.3 ' are independently selected from the group consisting of hydrogen, alkyl and benzyl, or alternatively, R.sup.1 and R.sup.1 ' or R.sup.3 and R.sup.3 ' with their respective nitrogen atoms independently form a phthalimido, succinimido, etc.; wherein R.sup.4, R.sup.5, and R.sup.6 independently are selected from the group consisting of hydrogen, --CHO, --COCH.sub.3, --COR.sup.7, etc.; therein said saccharides are optionally linked at the one position of said saccharid group; wherein R.sup.4 and R.sup.5, or R.sup.5 and R.sup.6, together comprise a methylidene, ethylidene, isopropylident, cyclohexylidene or benzylidene bridge, or R.sup.3 and R.sup.4, or R.sup.1 and R.sup.6, together independently form an intramolecular carbamate; wherein R.sup.5 is not hydrogen or glycosyl when R.sup.3 and R.sup.4, or R.sup.1 and R.sup.6, together independently form an intramolecular carbamate; with the provisio that at least two of R.sup.1, R.sup.1 ', R.sup.3, R.sup.3 ', R.sup.4, R.sup.5, and R.sup.6 are not hydrogen. Also provided are pharmaceutical compositions comprising the compound and methods of inhibiting binding of human immunodeficiency virus REV protein to RRE.